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ABSTRACT
Introduction In sub- Saharan Africa, the burden of non- 
communicable diseases (NCDs), particularly diabetes 
mellitus (DM) and hypertension, has increased rapidly in 
recent years, although HIV infection remains a leading 
cause of death among young- middle- aged adults. Health 
service coverage for NCDs remains very low in contrast 
to HIV, despite the increasing prevalence of comorbidity 
of NCDs with HIV. There is an urgent need to expand 
healthcare capacity to provide integrated services to 
address these chronic conditions.
Methods and analysis This protocol describes 
procedures for a qualitative process evaluation of INTE- 
AFRICA, a cluster randomised trial comparing integrated 
health service provision for HIV infection, DM and 
hypertension, to the current stand- alone vertical care. 
Interviews, focus group discussions and observations 
of consultations and other care processes in two 
clinics (in Tanzania, Uganda) will be used to explore the 
experiences of stakeholders. These stakeholders will 
include health service users, policy- makers, healthcare 
providers, community leaders and members, researchers, 
non- governmental and international organisations. The 
exploration will be carried out during the implementation 
of the project, alongside an understanding of the impact of 
broader structural and contextual factors.
Ethics and dissemination Ethical approval was granted 
by the Liverpool School of Tropical Medicine (UK), the 
National Institute of Medical Research (Tanzania) and 
TASO Research Ethics Committee (Uganda) in 2020. The 
evaluation will provide the opportunity to document the 
implementation of integration over several timepoints (6, 
12 and 18 months) and refine integrated service provision 
prior to scale up. This synergistic approach to evaluate, 
understand and respond will support service integration 
and inform monitoring, policy and practice development 
efforts to involve and educate communities in Tanzania 
and Uganda. It will create a model of care and a platform 
of good practices and lessons learnt for other countries 
implementing integrated and decentralised community 
health services.
Trial registration number ISRCTN43896688; Pre- results.
BACKGROUND
Non- communicable diseases (NCDs) have 
risen rapidly in Africa, alongside a continuing 
high burden of HIV infection. In sub- Saharan 
Africa (SSA), HIV/AIDS remains a major 
Strengths and limitations of this study
 ► The INTE- AFRICA trial will implement integration 
of HIV/non- communicable diseases (NCD) services 
in Tanzania and Uganda in response to an urgent 
need to respond to increased burden of NCDs, and 
expand capacity of healthcare systems to manage 
comorbidity.
 ► The INTE- AFRICA trial is based on a partnership be-
tween African and European researchers, working 
closely with policy- makers and other stakeholders.
 ► The process evaluation of INTE- AFRICA employs 
qualitative and observational methods at two fa-
cilities to explore and document stakeholder ex-
periences of integration of services, alongside an 
understanding of the impact of broader structural 
and contextual factors.
 ► The process evaluation works in tandem with 
quantitative evaluation of clinical efficacy and cost- 
effectiveness of the INTE- AFRICA trial.
 ► Limitations of the process evaluation may centre on 
patient drop- out, characteristics of the two selected 
sites, selection, information and social desirability 
bias and other external mitigating factors.
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cause of morbidity and mortality among young- middle- 
aged adults, but the region is also experiencing a rapidly 
rising burden of NCDs (particularly diabetes mellitus 
(DM) and hypertension), giving rise to a dual HIV- NCD 
epidemic.1–3 While lifestyle changes associated with urban-
isation and globalisation (such as eating habits and lack 
of physical exercise) underpin the ongoing demographic 
and epidemiological transition towards increasing NCDs, 
these changes also affect chronic conditions (such as 
HIV).1–3 The number of people in regular HIV care is 
rising,4 alongside the rate of NCDs in the SSA region, with 
hypertension representing the single largest risk factor 
for death, and DM which has seen a massive increase in 
prevalence in a short period of time.2 5–7 Patient popula-
tions in SSA are increasingly demonstrating younger age 
of onset of NCDs, with comorbidity of NCDs with HIV, 
and the impact of NCDs is particularly severe in popula-
tions affected by poverty.3 8–11
Since 2003, significant global investment and develop-
ment partner engagement has facilitated the establish-
ment of HIV screening and treatment programmes as 
the first large- scale chronic disease initiatives in Africa. 
Health services for HIV are stand- alone and vertically 
delivered. They have also been combined with decen-
tralisation and task shifting, which has enabled primary 
health centres to treat large numbers of patients. Non- 
clinically qualified health workers play a major role in 
supporting patients on HIV treatment, with almost 70% 
of people living with HIV- infection in regular care. In 
contrast, health service coverage for NCDs remains very 
low.2 12 Coordinated national NCD control and care 
programmes are relatively new with significant gaps in 
funding and operational evidence for programme imple-
mentation.11 13 For example, only about 5%–10% of 
persons with DM are thought to be in regular diabetes 
care, and the figure is likely to be similar for persons with 
hypertension.2 8 11 Furthermore, those in care experience 
insufficient health service provision for the diagnosis 
and management of DM and hypertension (medicines 
supply is patchy).2 12 14–17 HIV populations at risk of devel-
oping NCDs, and presenting with co/multimorbidities 
could potentially impact on the gains from the achieved 
scale- up of HIV care services.18
Hence, there is an urgent need to expand the capacity 
of healthcare systems in the SSA region to provide 
services for NCDs, either alongside or integrated, with 
HIV.19 As chronic conditions, DM, hypertension and 
HIV- infection require lifelong care. Key challenges to 
chronic care in SSA are linkage and retention in care, 
access and medicines adherence.20 21 As such, the infra-
structure and lessons learnt from the HIV chronic disease 
model can serve as important resources for the expan-
sion of NCD prevention, care and treatment. HIV chronic 
care management pathways, resources and infrastructure 
can be leveraged to integrate with newly developing 
NCD services, ultimately to strengthen the platform for 
NCD services and improve health outcomes for people 
with NCDs.22–24 Health systems have developed the expe-
rience managing HIV as a chronic disease, including 
linking and retaining patients in care and supporting 
treatment adherence in drugs, diagnostics procurement 
and other key health systems indicators.21 25–27 Integra-
tion can reduce duplication and fragmentation, stream-
line services by treat those with co/multimorbidities and 
potentially offer patient benefits relating to time and 
cost (figure 1). It could, however, also threaten service 
capacity by resulting in increased service demand and loss 
of clinical focus on one disease.
Despite the increase in academic and clinical interest in 
HIV/NCD integration in SSA,9 26 28–33 little evidence about 
integration in terms of both scope and generalisability 
exists. Extant evidence is limited to small scale feasibility 
studies in largely different contexts,34–40 despite suggesting 
that integrated care is an efficient use of resources 
compared with the standard of care and beneficial for 
patients’ NCD and HIV clinical outcomes.28 30 32 There is a 
lack of large scale or randomised and/or controlled eval-
uations and context- specific clinical, cost- effectiveness 
and process outcomes data constrains policy- making and 
development of integrated care models, which could 
strengthen health systems when tailored to the distinct 
needs of each specific SSA country.19 21 37 Such evidence is 
paramount to inform policy, government resource prior-
itisation and to develop integrated care models which 
strengthen health systems best suited to the needs of that 
specific SSA country. The INTE- AFRICA trial is conducted 
to respond to the insufficient existing evidence to substan-
tiate the benefits and sustainability of integrated care as 
well as the implementation of such programmes in the 
SSA setting. We present here the qualitative process eval-
uation protocol designed to evaluate INTE- AFRICA, a 
European Commission Horizon 2020 funded implemen-
tation research project (protocol number 19–100) oper-
ating in Tanzania and Uganda.
The INTE-AFRICA trial
INTE- AFRICA aims to implement and assess the effec-
tiveness of the integration of HIV, DM and hypertension 
services at the point of service delivery covering many 
health facilities where common approaches to clinical 
decision making, drug procurement and human resource 
Figure 1 Potential benefits of integrating diabetes, 
hypertension and HIV services for (A) DM and hypertension 
control, and (B) HIV control. DM, diabetes mellitus.
copyright.
 o
n
 O
ctober 23, 2020 at University of East Anglia. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-039237 on 7 October 2020. Downloaded from 
3Van Hout M- C, et al. BMJ Open 2020;10:e039237. doi:10.1136/bmjopen-2020-039237
Open access
management occur. The project will generate the research 
evidence needed by health services in Africa, to scale up 
and sustain chronic disease management and services in 
an integrated manner. We are also interested in observing 
changes in dynamics pertaining to stigma and discrimina-
tion associated with HIV.41
INTE- AFRICA team specifically chose Tanzania and 
Uganda as they are low- income countries and their public 
and private health facilities are strongly committed to 
providing services for NCD. However, their health systems 
struggle to scale up provision for diabetes and hyperten-
sion in the face of competing health demands, including 
HIV- infection (table 1). Tanzania and Uganda also share 
relevant characteristics with other countries in SSA. As 
such, the process evaluation has the potential to enhance 
the generalisability of integrated care to other similar 
settings by providing understanding of the determinants 
and mechanisms of the implementation process.
Our programme is underpinned by a participatory, 
multiactor approach which supports dialogue and 
knowledge exchange, fosters mutual understanding and 
provides input in policy agendas around diagnosis and 
treatment of DM, hypertension and HIV in an integrated 
clinic. The INTE- AFRICA conceptual framework is illus-
trated in figure 2.
INTE- AFRICA will test integrated health services at 
primary care centres for HIV- infection, diabetes and 
hypertension, by providing a ‘one- stop’ integrated care 
clinic for these conditions (the intervention). We will 
conduct a pragmatic parallel arm cluster randomised 
trial: 32 largely urban health facilities offering primary 
care services in the two countries will be randomised, with 
16 facilities allocated to deliver the intervention imme-
diately (intervention arm), and 16 facilities to continue 
with usual care (control arm). At each selected facility, 
cohorts of approximately 220 patients; 110 HIV infected 
and 110 NCD patients, will be enrolled to evaluate the 
primary research outcomes.
The primary care facilities will initiate and stabilise 
patients on treatment, manage complications (including 
referral to higher facilities) and conduct clinical and 
laboratory monitoring of patients for all three condi-
tions. Specific characteristics of integrated care in each 
‘one stop’ integrated care clinic are: concurrent manage-
ment of HIV, hypertension and DM in the same facility; 
management of patients with HIV, hypertension and 
DM by the same clinician or team of clinicians (nurses, 
counsellors other staff); integrated training of clinicians; 
single waiting area and queue; integrated health educa-
tion about all three conditions; one pharmacy with a 
single drug dispensing point; similar testing and cross- 
testing, for diagnosis and monitoring with the requisition 
of laboratory tests in the same place; and similar format 
of paper medical records for each condition kept in the 
same patient folder.
Patients who decline to participate in the research and 
trial participants in control arm clinics will continue to 
receive standard vertical healthcare delivery. Inclusion 
criteria for participation are: being over 18 years old; 
having confirmed HIV infection, DM or hypertension; 
living within the catchment population of the health 
facility; likely to remain in the catchment population 
for 6 months and willing to provide written informed 
consent. Very ill patients requiring in- patient care will 
be excluded. The research team will observe participants 
during clinic visits with additional reviews at 6 and 12 
months. Further details are provided in the full INTE- 
AFRICA trial protocol.
Qualitative process evaluation of the INTE AFRICA trial
The aim of the process evaluation of INTE- AFRICA is to 
explore the experiences, attitudes and practices of a wide 
variety of stakeholders during the process of programme 
implementation and to develop an understanding of 
the impact of broader structural and contextual factors 
on the implementation process of service integration. 
Process evaluations typically evaluate how and whether 
interventions are delivered as intended and whether such 
implementation is congruent with the theory underpin-
ning the intervention.25 42–44 Updated Medical Research 
Council guidance for evaluation of complex health inter-
ventions has recently recognised the value of process eval-
uation within trials stating, ‘it can be used to assess fidelity 
Table 1 key data on the country settings
 Tanzania Uganda
Income level Low Low
Population size 58 m(2018) 35 m(2016)
Estimated prevalence of 
hypertension from STEPS 
survey
26% 26%
Estimated prevalence 
of diabetes from STEPS 
survey15*
5%–10% 2%–5%
Estimated prevalence of HIV- 
infection
5.1% (2017) 6.2% (2017)
Doctors density/100 000 
population
3 (2014) 0.8 (2005)
*Diabetes estimate varies according to age and gender. Data 
are of variable quality but reference 11 shows that the overall 
median diabetes prevalence in 12 countries in Africa is 5%.
Figure 2 INTE- AFRICA conceptual model.
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and quality of implementation, clarify causal mechanisms 
and identify contextual factors associated with variation 
in outcomes.’25 Hence, the process evaluation in INTE- 
AFRICA is particularly focused on context, description of 
the intervention and its causal assumptions, implemen-
tation, mechanisms of impact and outcomes.25 Further 
we evaluate the extent to which resources and activities 
supporting the intervention function to deliver intended 
outputs, with subsequent improvements in outcomes.
A central focus lies in identifying contextually relevant 
strategies for successful implementation of service inte-
gration, and practical difficulties in adoption, delivery 
and maintenance to inform wider implementation.45 
We recognise that outcomes (eg, knowledge gained) of 
INTE- AFRICA are dependent on understanding cultures 
and contexts of the stakeholders (ie, patients, healthcare 
providers, policy- makers, community leaders/members, 
non- governmental organisations (NGO), international 
organisations and clinical researchers) involved and 
those surrounding service design and delivery as well as 
care seeking practices.
The role of social and behavioural science approaches 
to understanding individual experience, and the role 
of such contextual dynamics is central to this process 
evaluation. It aims to enhance understanding of issues 
related to the NCD and HIV agendas and service delivery 
approaches from all perspectives and stakeholders 
along the integration process. INTE- AFRICA will use a 
broad social behavioural approach to support commu-
nity engagement in research in Tanzania and Uganda, 
going beyond clinical trial recruitment and retention 
to improve NCD/HIV literacy. Behavioural and social 
science research strategies46 will allow NCD and HIV- 
related research to place the needs and perspectives of 
people living with NCD and/or HIV at the centre of the 
progression of clinical studies, such as INTE- AFRICA, and 
investigate participant motivations and decision- making 
processes related to preferences for or participation in 
different types of integrated and decentralised services.
Theoretical framework: Bronfenbrenner’s ecological model of 
behaviour
Process evaluation design, like healthcare interventions, 
requires a theoretical framework to structure the qualita-
tive and observational evaluation across sites. The chosen 
theoretical framework is Bronfenbrenner’s ecological 
model of behaviour47 48 used to conceptualise integrated 
care as events that disrupt complex social systems49 oper-
ating across multiple contextual levels. We are interested 
in better understanding the importance of context, which 
becomes especially relevant when comparing Tanzania 
and Uganda. For example, healthcare coverage and 
charging dynamics between countries and between HIV 
as opposed to NCD care differs. In Tanzania, while HIV 
services and drugs for HIV are free, patients are required 
to pay a direct user fee (unless elderly or very poor) or use 
their health insurance to pay for NCD drugs. Currently, 
there is a strategy to progress to single health insurance to 
support universal health coverage in Tanzania. In Uganda, 
HIV services are also free to all (public and private not 
for profit health facilities) and HIV drugs are always in 
stock. However, in Uganda while NCD services are free 
in public facilities, stockouts of laboratory reagents and 
NCD drugs are frequent, and patients have to pay a direct 
user fee to access them. There is also no national insur-
ance scheme in Uganda, only private insurance which is 
relatively expensive and optional.
Using the Bronfenbrenner theoretical framework, 
contextual factors are evaluated at the macro (universal 
vs partial coverage; free primary healthcare and drugs, 
affordability and users fees; fiscal policy, financial aspects 
at government level, funding barriers for chronic care 
management and barriers to government scale- up of 
service integration); meso (HIV/NCD drug ordering, 
drug delivery systems and continuity of supply, healthcare 
provider education and employment, community under-
standing and perspectives on multimorbidity) and micro 
(clinic and pharmacy level management, resources, 
patient/service user experience) levels (figure 3). These 
contextual factors, likely to influence implementation 
of integration and their effects, will be investigated to 
capture variation in adoption, delivery and maintenance 
outcomes as well as responses to the intervention. This 
will affect both reach and fidelity, which are hypothesised 
to be important factors in outcome differences.
To situate INTE- AFRICA within the Bronfenbrenner 
theoretical framework, we will develop a logic model. This 
model will set out contextual determinants of HIV and 
NCD care management in SSA and assess how integrated 
care components function to address these determinants 
to improve outcomes in the management and support of 
patients (table 2).
METHODS
Study setting
This will be a cohort study taking place in one ‘one- 
stop’ integrated care clinic per country. In Tanzania, the 
Figure 3 Potential contextual influences on INTE- AFRICA 
programme implementation cascade. CD, chronic disease; 
NCD, non- communicable diseases; NGO, non- governmental 
organisation; PEPFAR, President’s Emergency Plan for AIDS 
Relief.
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selected site is Temeke Regional Referral Hospital in Dar 
Es Salaam, a public tertiary health facility, with 465 staff, 
and serving a population of over 1 million. In Uganda, the 
selected site is the Kasangati Health Centre IV, Kasangati, a 
public district health facility located in the Wakiso District 
serving a population of over 2 million. Both provide a 
range of services to the community (primary care, HIV/
AIDs, NCDs, surgical, maternal and child health, health 
education, dental and pharmacy).
Study design
This protocol describes procedures for a qualitative 
process evaluation of the INTE- AFRICA pragmatic 
parallel arm cluster randomised trial comparing inte-
grated health service provision for HIV- infection, DM 
and hypertension with the current standard vertical care 
delivery model. The process evaluation works in tandem 
with the collection of selected clinical outcomes (eg, clin-
ical efficacy of different treatments) and health economic 
data (eg, costs and benefits of different approaches) to 
estimate the potential benefits to patients and health 
services at clinic and country level (protocol reported 
elsewhere).
Patient and public involvement
Patient and public involvement (PPI) throughout a 
programme of research enhances research quality and 
relevance by providing different perspectives and a sense 
of ownership. This protocol will adhere to the same 
principles, and will allow the voice of ‘service users’ and 
those affected to be heard, and utilised. Key stakeholders 
such as patients as service users and their families will be 
fully involved in guiding the research, acting as research 
participants, and in implementation of change in health 
service delivery and integrated care planning. All aspects 
of the process evaluation are underpinned by participa-
tory action health research and its success and usefulness 
will be grounded in PPI, participation and engagement 
in the form of patient/professional identification of 
research priorities, collaborations and partnerships, 
expert steering, community participation around health 
needs and optimal integrated services, awareness raising 
activities, development of print materials, toolkits and 
training for healthcare professionals.
It will use three qualitative research techniques: in- depth 
interviews with stakeholders (patients, healthcare 
Table 2 Logic model of programme inputs, processes and outcomes
Intervention inputs Changes in care processes Outcomes
Negotiation with national, district and 
local government health departments, 
NGOs and funders
Agreement about and support for service 
model, including reorganisation of clinics 
and staff
Commitment to ensure drug supply
 ► Reorganisation of clinics and staff to implement 
the model
 ► An effective, quality and sustainable funded 
drug supply chain
Negotiating lower drug prices
Supporting and monitoring drug 
ordering in each clinic
Providing buffer drug supplies to each 
clinic
Drugs always in stock  ► Increased diagnosis of comorbid conditions
 ► Increased retention and adherence
 ► Increased viral suppression, better control of 
blood pressure and blood glucose
 ► Less AIDS, cardiovascular disease and 
diabetes complications
 ► Lower patients costs (travel and absence from 
work)
 ► Less health service duplication and costs 
(health service costs might increase if more 
patients are diagnosed and are more adherent)
 ► Increase patient satisfaction
 ► Increased clinician satisfaction; less burn- out 
and absenteeism
 ► Reduce missed opportunities for improving 
care and health outcomes
Engagement with and support for 
clinicians and managers in each clinic
Clinicians and managers enable and 
support integration and find solutions to 
emerging problems
Provision of integrated service in each 
clinic (alongside and additional to 
existing services)
Trial participants attend integrated service
Avoid multiple visits for patients with 
multimorbidity
Training clinicians about integrated 
clinical management
Better diagnosis and treatment including 
attention to comorbid conditions
Community engagement Identify and enlist community 
organisations and resources to help with 
health education, tracing defaulters or 
patients who have difficulty attending 
clinic
Providing standardised stationery for 
integrated medical records; training 
clinicians to use it
Increased awareness by clinicians 
and patients about disease severity, 
comorbidity, adherence and control in 
individual patients
Improving monitoring and evaluation 
based on clinics registers and medical 
records
Regular data analysis and feedback to 
staff
Quality assurance and continuous improvement in 
the quality of care
Identifying effective health education Improve health education at clinics Healthier lifestyles
Increased adherence
NGO, non- governmental organisation.
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provider, policy- maker, NGO/international organisation, 
and clinical researcher); focus group discussions (FGD) 
with community leaders and community members; and 
clinic- based observations in one site per country. This 
design permits an assessment of the fidelity of INTE- 
AFRICA’s implementation, a detailed description of the 
processes, relationships, and contexts involved in the 
delivery of integrated care, and the identification of factors 
attributing to the failure or success of the programme. 
It thus addresses the ‘black box’ problem in interpreting 
trial results by improving understanding of the mecha-
nisms that connect particular intervention components 
to particular outcomes.50 The chosen approach will 
enhance social construction and acceptability of chosen 
decentralised integrated approaches, link outcomes to 
policy and advocacy and impact sustainability of HIV, 
DM and hypertension chronic disease service integra-
tion in two low and middle income countries. It provides 
the opportunity to document and refine INTE- AFRICA 
activities prior to a larger pragmatic trial or scale- up by 
Tanzanian and Ugandan governments. These syner-
gistic approaches to evaluate, understand and respond 
will support integration, support affordability, address 
barriers to government scale up and funding barriers 
for chronic care, inform surveillance, policy and practice 
development and improve efforts to involve and educate 
communities in Tanzania and Uganda. It will create a 
model and a platform of best practices and lessons learnt 
for other countries implementing integrated and decen-
tralised community health services for HIV and chronic 
disease. The process evaluation methods for each objec-
tive are described in table 3, including how each method 
maps onto the three different contextual levels.
Study population and recruitment
wenty- five patients and 10 healthcare providers in 
Temeke Regional Referral Hospital in Dar Es Salaam, 
Tanzania and Kasangati Health Centre IV, Kasangati, 
Uganda will be purposely selected and invited; at 6, 12 
and 18 months after the start of the trial, to reflect retro-
spectively on their experience of integration. Healthcare 
providers include the hospital/health centre overall in 
charge and pharmacist, and the ‘one- stop’ medical offi-
cers in- charge, trained clinicians managing HIV, diabetes 
and hypertension patients, pharmacist, laboratory tech-
nician, counsellors or nurses providing health education 
Table 3 Process evaluation design and data collection framework
Post- Integration. Data Collection at each Site* 6 months 12 months 18 months Contextual level
Observations of consultations, different processes 
and clinic flow at clinic levels and in non- clinical 
areas.
1 week 1 week 1 week Microcontext (facility and 
neighbourhoods)
In- depth phenomenological interviews with patients/
service users
25 25 25 Micro context (facility and 
neighbourhoods)
In- depth phenomenological interviews with 
healthcare providers at the clinic (hospital overall 
in charge, hospital pharmacist, the medical officers 
in- charge of the integrated clinic, trained clinicians 
managing HIV, diabetes and hypertension patients, 
pharmacist, laboratory technician, counsellors or 
nurses providing health education and counselling 
and nurses in the registration desk who are also 
responsible in taking vital signs)
10 10 10 Mesocontext (national to regional/
city)
Micro context (facility and 
neighbourhoods)
Semistructured interviews with Ministerial policy- 
makers and provincial/regional/district level clinical/
health senior management (Director for NCD, HIV 
and curative services).
– 5 5 Macrocontext (Global)
Meso context (national to regional/
city)
Semistructured interviews with NGO and 
international organisations (eg, WHO Country office, 
UNAIDS, PEPFAR, CDC)
– 5 5 Macrocontext (Global)
Meso context (national to regional/
city)
Focus group discussions (FGD) with community 
leaders (8–12 participants)
1 1 1 Microcontext (facility and 
neighbourhoods)
FGD gender specific with community members 
(8–12participants)
2 2 2 Microcontext (facility and 
neighbourhoods)
In- depth phenomenological interviews with clinical 
researchers
4 Microcontext (facility and 
neighbourhoods)
Meso context (national to regional/
city)
*The * refers to ‘Numbers indicated per country’.
CDC, Centers for Disease Control and Prevention; NGO, non- governmental organisation; PEPFAR, President’s Emergency Plan for AIDS 
Relief; UNAIDS, Joint United Nations Programme on HIV/AIDS.
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and counselling, and nurses in the registration desk who 
are also responsible in taking vital signs from patients. 
We will also collect qualitative data from interviews with 
Ministerial policy- makers and provincial/regional/
district level clinical/health senior management (direc-
tors for NCD, HIV and curative services); NGO and inter-
national organisations (eg, WHO Country office, Joint 
United Nations Programme on HIV/AIDS (UNAIDS), 
President’s Emergency Plan for AIDS Relief (PEPFAR), 
Centers for Disease Control and Prevention (CDC)) and 
clinical researchers; and conduct FGD with community 
leaders and community members. These numbers are 
expected to reach saturation (ie, the point that further 
information does not provide any additional variation 
in observed themes). We may replace participants, for 
example patients if there is significant loss to follow- up or 
refusal for repeated interviews. For instance, if a partici-
pant drops out at 12 months, we still have their 6- month 
experience documented, and we can replace with a new 
participant, invited to reflect on their 12- month retro-
spective experience. Where possible we will gender match 
interviewers with participants (particularly patients). 
Participants (patients, healthcare providers and others) 
will not be directly compensated bur rather they will be 
compensated for incurred transport costs to attend the 
interview/FGD, and provided with refreshments during 
the interview/FGD.
The following recruitment procedures will take place at 
each ‘one- stop’ integrated care clinic:
 ► Observations will be made in the integrated clinic 
in consultation with the hospital/health centre and 
‘one- stop’ clinic in- charges.
 ► Recruitment of patients will be supported by clinic 
nurses who will identify and approach selected partic-
ipants who have a minimum of 6 months experience 
of integration, and will be asked to consent to partake 
in an in- depth interview on the day they attend the 
clinic. INTE- AFRICA researchers will purposively 
sample women and men of different ages and explore 
any age/gender and condition ((HIV/hypertensive/
DM/multi/comorbid) related differences.
 ► Healthcare providers at the integrated clinic will be 
approached to participate in an in- depth interview 
on the day the INTE- AFRICA team are scheduled to 
attend.
 ► Ministerial policy- makers and provincial/regional/
district level clinical/health senior management will 
be identified and requested to participate in a semis-
tructured interview (face to face, online using Zoom 
or telephone).
 ► NGO and international organisations will be identi-
fied and requested to participate in a semistructured 
interview (face to face or telephone).
 ► Community leaders will be identified in the clinic 
catchment areas by virtue of their position while 
community members will be identified in consulta-
tion with the community leaders and invited to partic-
ipate in the FGDs.
 ► Clinical researchers will be invited to participate in an 
in depth interview at the 24- month end point.
Data collection
We will use the Empirical Phenomenological Psycholog-
ical (EPP) five- step method,51 which combines psycho-
logical, interpretative and idiographic components, to 
collect data. The data will garner an understanding of the 
complex social processes, of social, aged, gendered and 
culturally/community specific meanings and broaden 
the incremental understanding of the distinct lived expe-
rience of policy- makers, patients, healthcare providers, 
researchers and communities. We will balance the descrip-
tion of phenomena with the interpretation of insights 
and are cognisant of participant experiential phenomena 
and authors’ interpretation of associated meanings. It will 
yield an in- depth sociocultural understanding of patient- 
reported/participant- reported outcomes, their motiva-
tions, preferences, beliefs, expectations, identities, hopes 
and views on conditions, related stigma and of decision- 
making processes. This will provide better understanding 
of stakeholder and community positioning during inte-
gration. This understanding will inform policy and prac-
tice, ensure effective patient/service user education, 
position service users and their families to understand 
these conditions and interpret study outcomes and facili-
tate future HIV and chronic disease clinical studies.
Both descriptive patient- level data and rich sociobe-
havioural qualitative/observational data will be collected 
by a team of trained researchers in Tanzania and Uganda. 
Data collection will entail exploring the experiences, 
attitudes and practices of a wide variety of stakeholders 
during the process of INTE- AFRICA programme imple-
mentation and will develop an understanding of the 
impact of broader structural and contextual factors on the 
implementation process.10 45We will collect data on social 
behavioural and cultural aspects impacting implementa-
tion (eg, individual and community health risks, protec-
tive behaviours and health responses) within the broader 
social and political frameworks (government resources 
and barriers to sustaining integration), the practicalities 
of accessing, providing and sustaining integrated services 
(eg, staff time, resources, equity of access, supply chain 
dynamics and pharmacy components pertaining to drug 
types, drug/reagent availability and costs for integrated 
patients, catchment area/populations, quality of care, 
waiting room dynamics, record keeping and retention 
across multi/comorbidities, training gaps); and process 
indicators (eg, perceived stigma, acceptability of vertical 
vs integrated service designs, lay knowledge and aware-
ness, the dynamics of public vs private sector integration 
(where relevant to the participant), and bottlenecks to 
accessing services). We will also describe implementation 
of the intervention in terms of fidelity to the intended 
model of care, adaptations to the intervention during 
implementation, and dose and reach of intervention 
components actually delivered and received (such as 
numbers and proportions of eligible staff who received 
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integrated care training, numbers of proportions of 
patient participants who received all or most of their care 
from integrated services, and frequency of drug stock- 
outs). The latter data will be complemented by routinely 
collected quantitative data such as training attendance 
and medical records. We will document changes in health-
care provider roles, attitudes and patient relationships.
Interviews with patients/service users, healthcare 
provider and policy- maker/senior manager will include 
specific questions about their experience and manage-
ment of individuals with multimorbid HIV, hyperten-
sion and/or diabetes. These include their perceptions 
of INTE- AFRICA; impacts of INTE- AFRICA on the 
provision of integrated HIV/AIDS care and NCD care, 
and relationships with NGO and international organi-
sations; changes in health provider roles, attitudes and 
patient relationships; impacts of the INTE- AFRICA imple-
mentation context on trial and health economic cost 
outcomes; impacts of the INTE- AFRICA intervention on 
an integrated health systems approach to care (medicine 
supplies, record keeping, service user education, clinical 
care pathways, data management, staff training); and 
barriers to and facilitators of change and future sustain-
ability of integrated care provision. We will assume a more 
pragmatic approach when garnering perspectives from 
higher level stakeholders involved in health policy and 
practice generation, and NGO and international organ-
isations (eg, WHO country offices, UNAIDS, PEPFAR, 
CDC) providing peripheral supports and guidance. We 
are especially interested in better understanding the 
complexities around government scale up and resource 
allocation for chronic care (eg, decentralisation, finan-
cial planning, identification of potential funding sources 
at ministry levels, subsidised NCD drugs and by interna-
tional donors (CDC, PEPFAR, UNAIDS) (table 3).
Data analysis and synthesis
The analysis of qualitative data will be iterative, moving 
between data collection and analysis to test emerging 
theories. Field notes of observations will be analysed 
thematically to provide a description of the process and 
content involved in adapting and delivering the inter-
vention. Audio recordings of interviews and FGDs will 
be transcribed verbatim by competent and experienced 
social scientists, with a subsample transcribed using 
conversation analytic conventions. Translation from 
local languages (eg, Swahili, Luganda) into English will 
be performed for easy sharing with the study partners. 
Translation will occur using a back- translation method 
for consistency. An electronic data management package 
(eg, NVivo) will be used to manage the qualitative data 
analysis at the respective country levels. The analysis of 
the observational data will require knowledge obtained 
from health professional interviews at different levels 
to compare how reported experience, and different 
accounts of patient and professional perspectives relate 
to actual implementation of INTE- AFRICA scenarios: (1) 
when DM and hypertension services are integrated with 
HIV- infection services and (2) comparing countries. Care 
will be taken to identify and follow up deviant cases which 
do not fit into emerging theories. Reliability and validity 
of the analysis is optimised through iterative data collec-
tion, the use of a multi- method design incorporating 
interviews, FGD and observations and the ongoing discus-
sion of findings within the research team for scrutiny and 
feedback.52 53
The chosen phenomenological approach (EPP) to 
collecting and analysing data, usually used in psycholog-
ical research, reveals the structures of subjective expe-
rience and meaning of a lived phenomenon (in first 
person point of view). It follows to some extent Husserl’s 
principle of active efforts to ‘bracket out’ the researchers’ 
theoretical preunderstanding in the first steps of a text 
analysis.51 The ‘bracketing’, however, does not exclude 
an empathetic, psychological focus in the analysis on the 
experiences of the researched phenomenon as it is lived 
by the informant and what it means is to her or him. In the 
context of INTE- AFRICA, researchers in both countries 
will strive to get an empathetic understanding of the text, 
and hence do not apply their professional prior knowl-
edge about integration. The analysis of the observational 
data will also require knowledge from health professional 
interviews to compare how reported experience relates to 
actual implementation of integration at the clinic level.
We will conduct a stepwise EPP analysis in five steps. 
First, the text will be read several times to get a good 
grasp of how the informant spoke about the researched 
phenomenon of integration. In this step, theoretical 
reflection will be withheld. Second, the whole text will 
be divided into meaning units of a whole paragraph or a 
single word. Third, the informant’s personal language will 
be transformed, unit by unit, to the researchers’ language. 
The researchers will discuss the transcription unit by unit. 
When different interpretations occur, the researchers will 
return to the interview text and discuss in a free, imagi-
native process until agreement can be reached through 
negotiated consensus. Fourth, the text will be screened in 
a search for comprehensive themes. The text will be inter-
preted with connection to the researchers’ theoretical 
knowledge in an interchange between the original data, 
the transformed units and the researchers’ theoretical 
preunderstanding about integration. The meaning units 
will be assorted into appropriate themes and thus consti-
tute a general structure of the phenomenon of integrated 
care. Fifth, this essential structure will penetrate all the 
revealed themes and thus the meaning of the researched 
phenomenon of integrated care to the informant.
Credibility and transferability
The process evaluation protocol adheres to recommenda-
tions intended to facilitate the standardisation of process 
evaluation design and reporting.43 It provides a unique 
opportunity to document implementation and collabora-
tively refine integrated care in two SSA countries. This 
makes possible the synthesis of results of similar studies 
elsewhere in the SSA region in future. In order to ensure 
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credibility, while we use different methods of data collec-
tion (qualitative/observational), and operate concur-
rently with clinical outcomes data and health economics 
analysis, we will also add a further layer of triangulation 
of sources in terms of perspectives across stakeholders 
and across conditions (HIV/hypertension/DM/multi/
comorbidity) when raising the abstraction level. Triangu-
lation of sociobehavioural qualitative and observational 
data during analysis will occur in order to understand how 
different types of evidence enhance the overall interpreta-
tion of how INTE- AFRICA was implemented, and what the 
additional health economic and clinical data are, drawing 
case comparisons across clinics and across countries, and 
developing possible explanations for implementation 
variation. The data, when combined and triangulated 
across these multi stakeholder perspectives, will provide a 
‘thick description’, of how the intervention was delivered, 
maintained and experienced by stakeholders.10 45 It will 
also offer explanations for observed variation over time 
and between countries, and detailed insight into the inter-
action between different contextual features and compo-
nents of integration of NCD or HIV/NCD services. It will 
also facilitate triangulation of information across stake-
holders, clinics and countries. This approach will help 
to support transferability to other settings, by identifying 
factors which are plausibly and/or consistently related to 
successful or unsuccessful delivery of intervention compo-
nents. We recognise the potential for selection and infor-
mation bias as limitations of the trial itself, and mitigate 
by using a random sampling approach, defining charac-
teristics in a cohort, using a standardised approach to 
collecting data with continual assessment of information 
bias, and ensuring that research personnel are unaware 
of participant disease status. We will address social desir-
ability in the process evaluation by only providing brief 
information at the outset of the evaluation in order to 
avoid priming, using an interview schedule approved by 
a panel of INTE- AFRICA experts in terms of sensitivity, 
conducting qualitative research using skilled interviewers 
with limited power relationship between interviewer and 
participant, conducting the interviews in a safe and secure 
setting where the participant feels comfortable, briefing 
them that there is no right and wrong answer, and finally 
by encouraging them to use anecdotes and experiential 
evidence to support their views.
Emerging theories and the relationship of the data 
to the conceptual literature underpinning the inter-
vention will be discussed and refined at INTE- AFRICA 
research team meetings throughout the project. We 
envisage utilising the public understanding of science 
theory54 to unpack how patients and their communities 
in Tanzania and Uganda understand and use different 
knowledge on HIV and NCDs in their lives. This could 
be facilitated by understanding how they create meaning 
from scientific findings relating to NCDs and HIV and if, 
how, and to what degree they incorporate these findings 
into their everyday lives. This theory has the capacity to 
shift public attitudes by connecting and communicating 
the development of innovative scientific concepts in the 
medical field (in this instance integration of HIV/NCD 
services in Tanzania and Uganda) to the non- scientific 
public, and thereby enhance education, training cascade, 
health policy and practice, and ultimately public under-
standing of multimorbidities and sustainable routes to 
care. Further, it will create a platform for the sharing of 
lessons learnt, best practices and context adaptation of 
the final integrated model of care in other African coun-
tries (clinical care policies and practice, staff cascade of 
training, service user education and community aware-
ness raising).
ETHICAL CONSIDERATIONS
Ethical approval for the evaluation has been granted by 
the research ethics committees of the Liverpool School 
of Tropical Medicine (UK), the National Institute of 
Medical Research (Tanzania) and TASO Research Ethics 
Committee (Uganda). The key ethical principles of 
voluntary and informed participation, confidentiality and 
safety of participants will be used in all researcher and 
participant interactions. Written consent for interviews 
and observations will be obtained from all participants. 
All participants will be provided with written information 
about the research, this will be explained verbally, and 
informed that their participation is voluntary and that 
they may withdraw from participation at any time. Safety 
and confidentiality of all data will be ensured by: (1) 
encrypting all transcriptions with a password- protected 
code; (2) storing all data in a secure, encrypted database 
accessible only to authorised persons on the research 
team; (3) delinking all personal information of partici-
pants from the data collected and stored. Each partici-
pant will have a unique identification number.
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